Inovio Pharma INO

$1.71 +0.02 (1.18%)

Valuation

Market cap
179,597,000
Revenue TTM
$70,000
Net income TTM
$-84,950,000
P/E (trailing)
0.00
P/E (forward)
—
Profit margin
-121,357.14%
Debt to equity
0.00

Trading

Volume
9,943,300
Avg volume
13,194,395
Day's range
$1.63 – $1.79
Shares out
110,182,000
Stochastic %K
97%
Beta
1.71
Analysts
Strong Buy
Price target
$6.33

Price

Company profile

Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses SynCon, to help engineer precisely designed plasmid DNA plasmids, as well as CELLECTRA smart devices technology that facilitates deliver...

Show more

Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses SynCon, to help engineer precisely designed plasmid DNA plasmids, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. The company's lead product candidate is INO-3107 for HPV-related recurrent respiratory papillomatosis and is under Phase 1/2 trial. Its products in pipeline include VGX-3100 for the treatment of HPV-related cervical high-grade squamous intraepithelial lesions; INO-3112 for the treatment of HPV-related Oropharyngeal squamous cell carcinoma and is under Phase 2 trial; INO-5401 for the treatment of glioblastoma multiforme and is under Phase 2 trial; INO-4201 for Ebola Virus Disease and is under Phase 1b trial; INO-4800 for COVID-19 and is under Phase 2/3 trial; and INO-6160 for the treatment of human immunodeficiency virus and is under Phase 1 trial. The company's partners and collaborators ApolloBio Corporation, AstraZeneca, Coherus Biosciences, Defense Advanced Research Projects Agency, HIV Vaccines Trial Network, Kaneka Eurogentec, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Plumbline Life Sciences, Regeneron Pharmaceuticals, Richter BioLogics, the University of Pennsylvania, and The Wistar Institute. The company was incorporated in 1983 and is headquartered in Plymouth Meeting, Pennsylvania.

Industry
Biotechnology
Sector
Healthcare
Phone
267 440 4200
Website
https://www.inovio.com
Address
660 West Germantown Pike, Suite 110, Plymouth Meeting, United States

Latest news

Stocktwits

soooooooo000OOO000ooooor Nov 19, 10:44 PM
$INO One of the very few stocks to tell the macro to suck its d today.
0 replies
1of402Phase2TrialUSA Nov 19, 10:37 PM
$INO $PGEN Inovio has zero Debt. Precigen has $130,000,000 + in Long Term debt.
1 replies
GridironGainz Nov 19, 10:36 PM 0 replies
Bunster Nov 19, 10:33 PM
$INO just about all the small bios on my WL gotslammed today but not INO
0 replies
BKuma29 Nov 19, 10:13 PM
$INO This new job posted today at Siegfried for OT System Engineer makes me feel secured as an investor in Inovio because they take manufacturing seriously and make sure there are no hiccups along the way especially with the FDA looking closely. Unless anyone can correct me I’m assuming they get the DNA plasmids from Richter Biologics in Germany and process it into the vials for Inovio at Irvine California USA.
1 replies
soooooooo000OOO000ooooor Nov 19, 9:55 PM
$INO Sexiest stock in the entire market.
0 replies
RaphaelRapoport Nov 19, 9:47 PM
$INO when you see a big drop out of nowhere that’s when you buy. It’s final Shake out attempts before they release big PR. See you all there :) Made 20k first round let’s do 50k this second round
1 replies
Traderjuan Nov 19, 9:45 PM
$INO Mark my words. 2+ Next week. The big Boys load now. I see now $ 10-15 with China and EU News in 2027. $QQQ out $XBI BioTechs will have a huge Comeback. Shifting & Difting. $NVAX Patience will lead this into triple digits in 2-3 Yesrs. Long!
0 replies